The Institute for Clinical and Economic Review on Monday, Sept. 24, released a draft evidence report on the clinical effectiveness and value of biologics used to treat asthma.
According to a press release, the report looks at:
- Sanofi/Regeneron’s Dupixent;
- Teva’s Cinqair; and
- AstraZeneca’s Fasenra.
The report will be open for public comment until 5 p.m. Oct. 22.
A public meeting of the Midwest Comparative Effectiveness Public Advisory Council will deliberate on the report when it convenes Nov. 29.
To read the draft evidence report, click here.